(Q39294871)

10 September 2017

1 reference

title

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer (English)

1 reference

10 September 2017

2

Lesley J Scott

1 reference

10 September 2017

Esther S Kim

1

1 reference

10 September 2017

publication date

9 May 2017

1 reference

10 September 2017

1 reference

10 September 2017

volume

12

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

373-383

1 reference

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Palbociclib and Letrozole in Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0492-7

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28488183

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28488183

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-017-0492-7

1 reference

10 September 2017

1 reference